Fenwick Represents Morphic Therapeutic in $276 Million Public Offering

Fenwick represented Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, in its underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Morphic received gross proceeds of approximately $276.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Jefferies, TD Cowen, BMO Capital Markets, RBC Capital Markets and Wells Fargo Securities acted as joint book-runners for the offering. More information can be obtained from Morphic’s announcement.

The Fenwick transaction team included corporate partners Julia Forbess, Robert Freedman and Effie Toshav, and associates Beth Clarke, Alexej Ladonnikov and Jing Liu.